Captopril alleviates lung inflammation in SARS-CoV-2-infected hypertensive mice.
Zool Res
; 42(5): 633-636, 2021 Sep 18.
Article
in English
| MEDLINE | ID: covidwho-1369995
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent responsible for the global coronavirus disease 2019 (COVID-19) pandemic. Numerous studies have demonstrated that cardiovascular disease may affect COVID-19 progression. In the present study, we investigated the effect of hypertension on viral replication and COVID-19 progression using a hypertensive mouse model infected with SARS-CoV-2. Results revealed that SARS-CoV-2 replication was delayed in hypertensive mouse lungs. In contrast, SARS-CoV-2 replication in hypertensive mice treated with the antihypertensive drug captopril demonstrated similar virus replication as SARS-CoV-2-infected normotensive mice. Furthermore, antihypertensive treatment alleviated lung inflammation induced by SARS-CoV-2 replication (interleukin (IL)-1ß up-regulation and increased immune cell infiltration). No differences in lung inflammation were observed between the SARS-CoV-2-infected normotensive mice and hypertensive mice. Our findings suggest that captopril treatment may alleviate COVID-19 progression but not affect viral replication.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Captopril
/
SARS-CoV-2
/
COVID-19
/
Hypertension
/
Lung Diseases
/
Antihypertensive Agents
Type of study:
Etiology study
Topics:
Long Covid
Limits:
Animals
Language:
English
Journal:
Zool Res
Year:
2021
Document Type:
Article
Affiliation country:
J.issn.2095-8137.2021.206
Similar
MEDLINE
...
LILACS
LIS